摘要
目的:探讨连花清瘟颗粒联合洛匹那韦/利托那韦治疗新型冠状病毒肺炎(COVID-19)的疗效与安全性。方法:回顾性选取截至2020年3月24日安徽医科大学附属六安医院收治的50例住院期间应用连花清瘟颗粒联合洛匹那韦/利托那韦片治疗的COVID-19患者资料,总结和分析治疗前后临床症状、影像学检查和实验室检查的变化及不良反应发生情况。结果:50例患者经连花清瘟颗粒联合洛匹那韦/利托那韦治疗后的临床症状较治疗前明显改善。肺部影像学检查结果显示,平均改善时间为(10.83±5.91)d。经7 d治疗后,实验室检查各项指标(包括白细胞、淋巴细胞、丙氨酸转氨酶、天冬氨酸氨基转移酶、肌酸激酶、乳酸脱氢酶及C反应蛋白等)正常患者数均较治疗前增加,其中C反应蛋白水平的改善情况最为明显。50例患者中,发生不良反应24例,多为轻症,对症治疗后均缓解。结论:在COVID-19尚无特效治疗药物的情况下,连花清瘟颗粒联合洛匹那韦/利托那韦治疗方案可供临床治疗经验性选择,在用药过程中需密切关注不良反应,保障用药安全。
OBJECTIVE:To probe into the efficacy and safety of Lianhua Qingwen granules combined with lopinavir/ritonavir in the treatment of COVID-19.METHODS:Clinical data of 50 patients with COVID-19 who were treated with Lianhua Qingwen granules combined with lopinavir/ritonavir tablets were retrospectively selected until Mar.24,2020 in Lu’an Hospital Affiliated to Anhui Medical University.Changes of clinical symptoms,imaging examination and laboratory examination before and after treatment and incidence of adverse drug reactions were summarized and analyzed.RESULTS:The clinical symptoms of 50 patients were significantly improved after treatment with Lianhua Qingwen granules combined with lopinavir/ritonavir.The results of lung imaging examination showed that the average improvement time was(10.83±5.91)d.After 7 d of treatment,the number of patients with normal indicators(including white blood cells,lymphocytes,alanine aminotransferase,aspartic acid aminotransferase,creatine kinase,lactate dehydrogenase and C-reactive protein)increased compared with those before treatment,and the improvement of C-reactive protein level was the most significant.Adverse drug reactions occurred in 24 of the 50 patients,most of which were mild and all resolved after symptomatic treatment.CONCLUSIONS:In the absence of specific therapeutic drugs for COVID-19,Lianhua Qingwen granules combined with lopinavir/ritonavir can be used as an empirical choice for clinical treatment.Adverse drug reactions should be closely monitored during the medication process to ensure the medication safety.
作者
夏一淼
王法财
沈炳香
聂松柳
XIA Yimiao;WANG Facai;SHEN Bingxiang;NIE Songliu(Dept.of Pharmacy,Lu’an Hospital Affiliated to Anhui Medical University(Lu’an People’s Hospital),Anhui Lu’an 237005,China)
出处
《中国医院用药评价与分析》
2021年第2期179-181,184,共4页
Evaluation and Analysis of Drug-use in Hospitals of China